What Is BPC-157?
BPC-157 (Body Protection Compound-157) is classified as a body protective compound peptide. Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
It is extensively evaluated in laboratory and clinical settings for its potential to drive injury recovery, gut healing, tissue repair, reduced inflammation. Researchers target BPC-157 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Excellent research safety profile; commonly used for recovery. Not FDA-approved. Most evidence from animal models. FDA restricted use in compounded medications in Sept 2023.
How Does BPC-157 Work?
Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
At the molecular level, BPC-157 operates through pathways characteristic of the Body Protective Compound class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with injury recovery, gut healing, tissue repair, reduced inflammation.
Expected Research Timeline
Weeks 2–4
Noticeable mobility improvement; significant reduction in injury-site swelling
Months 2–3
Substantial tissue remodeling; most acute injuries showing measurable repair
Long-Term
Full tendon/ligament functional recovery in most preclinical models; sustained GI remission
What Does the Research Say?
The following are key findings from peer-reviewed studies on BPC-157, indexed on PubMed and equivalent databases:
[1]BPC-157 tendon, ligament, and gut healing effects
Comprehensive review demonstrating potent tendon, ligament, and gut healing effects across multiple preclinical models.
Evidence: preclinical[2]Stable gastric pentadecapeptide BPC 157 gastrointestinal tract healing
Robert et al. demonstrate BPC-157 heals GI ulcers, fistulas, and inflammatory bowel lesions in rats via cytoprotective pathways. Published in Current Pharmaceutical Design.
Evidence: preclinical[3]BPC-157 accelerates Achilles tendon healing in rats
Staresinic et al. show BPC-157 accelerates healing of transected Achilles tendons, enhancing tendon fibroblast outgrowth and survival via FAK-paxillin signaling.
Evidence: preclinical[4]BPC-157 systematic review: musculoskeletal healing (2025)
Systematic review of 35 preclinical and 1 clinical study (1993-2024). BPC-157 promotes angiogenesis, collagen synthesis, and reduces inflammatory cytokines across muscle, tendon, ligament, and bone injury models.
Evidence: preclinical[5]BPC-157 and neuroprotection: stroke and spinal cord models
Preclinical evidence showing BPC-157 counteracts stroke-induced neuronal damage and improves functional recovery after spinal cord compression in rats.
Evidence: preclinical[6]BPC-157 angiogenic and vascular protective effects
Demonstrates BPC-157's strong angiogenic potential via VEGFR2-Akt-eNOS pathway activation, endothelium protection, and reversal of thrombus formation.
Evidence: preclinicalSafety & Side Effects
Excellent research safety profile; commonly used for recovery. Not FDA-approved. Most evidence from animal models. FDA restricted use in compounded medications in Sept 2023.
| Side Effect | Incidence | Severity |
|---|---|---|
| Lightheadedness | ~5% of users | mild |
| Nausea (especially oral route) | ~3-5% of users | mild |
| Vivid dreams | ~5% of users | mild |
| Euphoria / mood lift | ~8% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
BPC-157 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is BPC-157 Used?
Route
SubQ
Dose Range
500–500 mcg
Frequency
7x/wk
Cycle
8–8 wk
Timing: Morning or split AM/PM
Notes: Often run 250mcg 2x/day for injuries. Can be injected near injury site.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
BPC-157 vs. Related Compounds
Where to Source BPC-157 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is BPC-157?
BPC-157 is a body protective compound peptide. Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
What are the primary research benefits of BPC-157?
Published research identifies primary mechanisms targeting: Injury recovery, gut healing, tissue repair, reduced inflammation. These findings come from 6+ peer-reviewed studies indexed in our database.
What is the half-life of BPC-157?
In published pharmacokinetic data, BPC-157 demonstrates a half-life of approximately 4 hours.
Is BPC-157 FDA approved?
BPC-157 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of BPC-157?
Reported side effects in published literature include Lightheadedness (~5% of users), Nausea (especially oral route) (~3-5% of users), Vivid dreams (~5% of users), Euphoria / mood lift (~8% of users). Most are classified as mild in severity.
How is BPC-157 administered?
In research settings, BPC-157 is typically administered via SubQ. Often run 250mcg 2x/day for injuries. Can be injected near injury site.
Sources
- BPC-157 tendon, ligament, and gut healing effects. View on PubMed
- Stable gastric pentadecapeptide BPC 157 gastrointestinal tract healing. View on PubMed
- BPC-157 accelerates Achilles tendon healing in rats. View on PubMed
- BPC-157 systematic review: musculoskeletal healing (2025). View on PubMed
- BPC-157 and neuroprotection: stroke and spinal cord models. View on PubMed
- BPC-157 angiogenic and vascular protective effects. View on PubMed